| 9.82 0.22 (2.29%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.52  |
1-year : | 13.46 |
| Resists | First : | 9.86 |
Second : | 11.52 |
| Pivot price | 9.32 |
|||
| Supports | First : | 8.73 |
Second : | 8.03 |
| MAs | MA(5) : | 9.61 |
MA(20) : | 9.27 |
| MA(100) : | 9.42 |
MA(250) : | 9.53 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 89.1 |
D(3) : | 84 |
| RSI | RSI(14): 63.3 |
|||
| 52-week | High : | 11.8 | Low : | 7.73 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PRTA ] has closed below upper band by 7.9%. Bollinger Bands are 30% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.88 - 9.92 | 9.92 - 9.95 |
| Low: | 9.37 - 9.42 | 9.42 - 9.46 |
| Close: | 9.74 - 9.82 | 9.82 - 9.88 |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Sat, 05 Sep 2026
Prothena stock holds near USD 9.60 after market cap update - AD HOC NEWS
Thu, 03 Sep 2026
Prothena Director William P. Scully Acquires 27,000 Shares in Open Market - Kalkine Media
Wed, 02 Sep 2026
Responsive Playbooks and the PRTA Inflection - news.stocktradersdaily.com
Fri, 28 Aug 2026
Prothena Stock Price Forecast. Should You Buy PRTA? - StockInvest.us
Wed, 19 Aug 2026
Trustee controls a tenth of Prothena (PRTA) stock via trusts - Stock Titan
Tue, 18 Aug 2026
Prothena (PRTA) Holds Steady Near $8.88 as Shares Sit Between Key Support and Resistance - Positive Gamma - vinanet.vn
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 3.498e+007 (%) |
| Held by Institutions | 21.5 (%) |
| Shares Short | 8,370 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.904e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -80.7 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 850.2 % |
| Return on Equity (ttm) | -10.7 % |
| Qtrly Rev. Growth | 5.453e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.63 |
| Dividend | 0 |
| Forward Dividend | 8.17e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|